Literature DB >> 24419026

[Mortality and readmission in hospitalized cirrhotic patients in a General Hospital from Lima, Peru].

Alexander Malpica-Castillo1, Ray Ticse1, María Salazar-Quiñones1, Lester Cheng-Zárate1, Vanessa Valenzuela-Granados2, Jorge Huerta-Mercado Tenorio3.   

Abstract

UNLABELLED: Liver cirrhosis is a public health problem. In Peru, is the leading cause of death in liver diseases. In addition, patients with chronic liver disease and cirrhosis are at increased risk for readmission.
OBJECTIVES: To determine the frequency of mortality and readmission at 3 months, and clinical-epidemiological characteristics of hospitalized cirrhotic patients in a general hospital.
MATERIALS AND METHODS: Data were collected prospectively of hospitalized cirrhotic patients in the Hospital Nacional Cayetano Heredia,Lima,Peru, from October 2011 to October 2012; telephone follow-up was at 3 months after hospital discharge.
RESULTS: The study included 96 patients. The mean age was 59.2 years. The most common etiology of cirrhosis was alcohol (45.8%) and the main reason for hospitalization was upper gastrointestinal bleeding (29.2%). Global mortality was 39.6% (38 patients), from them, 63.2% (24/38) were inpatients, its main cause was septic shock 31.5% (12/38). Forty-four percent of the deceased had infection as complication. Hospital readmission was 42.8% (33/77) and 36.3% of them died.
CONCLUSIONS: Hospitalized cirrhotic patients showed high mortality at 3 months, these patients at discharge revealed a high readmission within 3 months of follow up.

Entities:  

Mesh:

Year:  2013        PMID: 24419026

Source DB:  PubMed          Journal:  Rev Gastroenterol Peru        ISSN: 1022-5129


  1 in total

1.  Morbimortality Associated with Liver Cirrhosis in Peru: An Ecological Analysis for the Period of 2004-2016.

Authors:  Daniela Rojas-Acuña; Nilo Polo-Samillan; Angie Z Vasquez-Chavesta; Crist Escalante-Arias; Cristhian J Rios-Perez; Carlos J Toro-Huamanchumo
Journal:  Int J Environ Res Public Health       Date:  2022-07-25       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.